Problems with CATIE. Phase 1: Looking back--what the clinician needs to know.
Washburn
Carl F
CF
Hartford Hospital/The Institute of Living, 80 Seymour Street, P.O. Box 5037, Conklin Building Suite 401, Hartford, CT 06102-5037, USA. cwashbu@harthosp.org
D018687:Antidepressive Agents, Second-Generation / Q000008:administration & dosage* / Q000191:economics; D001480:Basal Ganglia Diseases / Q000188:drug therapy; D001569:Benzodiazepines; D017321:Clinical Trials, Phase I as Topic; D003362:Cost-Benefit Analysis; D003987:Dibenzothiazepines; D006801:Humans; D000077152:Olanzapine; D010879:Piperazines; D000069348:Quetiapine Fumarate; D016032:Randomized Controlled Trials as Topic; D012306:Risk; D018967:Risperidone; D012559:Schizophrenia / Q000188:drug therapy*; D013844:Thiazoles
D018687:Antidepressive Agents, Second-Generation; D003987:Dibenzothiazepines; D010879:Piperazines; D013844:Thiazoles; D001569:Benzodiazepines; D000069348:Quetiapine Fumarate; C092292:ziprasidone; D018967:Risperidone; D000077152:Olanzapine